{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:49:49Z","timestamp":1794660589107,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Horizontal Project of Tianjin Nankai Hospital","award":["NKYY-2022-003"],"award-info":[{"award-number":["NKYY-2022-003"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170887"],"award-info":[{"award-number":["82170887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CD44 plays a key role in the communication of CSCs with the microenvironment and the regulation of stem cell properties. UALCAN was used to analyze the expression of CD44 in bladder cancer (BLCA) and normal tissue. The UALCAN was utilized to analyze the prognostic value of CD44 in BLCA. The TIMER database was used to explore the relationship between CD44 and PD-L1; CD44 and tumor-infiltrating immune cells. The regulatory effect of CD44 on PD-L1 was verified by cell experiments in vitro. IHC confirmed the results of the bioinformatics analysis. GeneMania and Metascape were used to analyze protein\u2013protein interaction (PPI) investigations and functional enrichment analysis. We found that BLCA patients with high CD44 expression had worse survival than those with low CD44 expression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). IHC and the TIMER database results showed that CD44 expression was positively correlated with PD-L1 expression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). At the cellular level, the expression of PD-L1 was significantly inhibited after CD44 expression was inhibited by siRNA. Immune infiltration analysis showed that CD44 expression levels in BLCA were significantly correlated with immune infiltration levels of different immune cells. IHC staining results further confirmed that the expression of CD44 in tumor cells was positively associated with the number of CD68\n                    <jats:sup>+<\/jats:sup>\n                    macrophages and CD163\n                    <jats:sup>+<\/jats:sup>\n                    macrophages (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). Our results suggest that CD44 is a positive regulator of PD-L1 in BLCA and may be a key regulator of tumor macrophages infiltration and may be involved in M2 macrophage polarization. Our study provided\u00a0new insights into the prognosis and immunotherapy of BLCA patients through macrophage infiltration and immune checkpoints.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-33915-4","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T11:02:15Z","timestamp":1686740535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Shuangqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongjing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"33915_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2020.00102","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu, S. et al. Traditional classification and novel subtyping systems for bladder cancer. Front. Oncol. 10, 102 (2020).","journal-title":"Front. Oncol."},{"issue":"3","key":"33915_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(3), 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"issue":"6","key":"33915_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"33915_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung, C., Dinh, T. & Lee, J. The health economics of bladder cancer: An updated review of the published literature. Pharmacoeconomics 32(11), 1093\u20131104 (2014).","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"33915_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23(10), 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"issue":"1","key":"33915_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.stem.2018.11.017","volume":"24","author":"C Saygin","year":"2019","unstructured":"Saygin, C. et al. Targeting cancer stemness in the clinic: From hype to hope. Cell Stem Cell 24(1), 25\u201340 (2019).","journal-title":"Cell Stem Cell"},{"issue":"4","key":"33915_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/mp.52.4.189","volume":"52","author":"S Goodison","year":"1999","unstructured":"Goodison, S., Urquidi, V. & Tarin, D. CD44 cell adhesion molecules. Mol. Pathol. 52(4), 189\u2013196 (1999).","journal-title":"Mol. Pathol."},{"issue":"12","key":"33915_CR8","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biom11121850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati, M. et al. CD44: A multifunctional mediator of cancer progression. Biomolecules 11(12), 1850 (2021).","journal-title":"Biomolecules"},{"issue":"9","key":"33915_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","volume":"4","author":"Y Yan","year":"2015","unstructured":"Yan, Y., Zuo, X. & Wei, D. Concise review: Emerging role of CD44 in cancer stem cells: A promising biomarker and therapeutic target. Stem Cells Transl. Med. 4(9), 1033\u20131043 (2015).","journal-title":"Stem Cells Transl. Med."},{"issue":"19","key":"33915_CR10","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1158\/0008-5472.CAN-20-1079","volume":"80","author":"KE Gomez","year":"2020","unstructured":"Gomez, K. E. et al. Cancer cell CD44 mediates macrophage\/monocyte-driven regulation of head and neck cancer stem cells. Cancer Res. 80(19), 4185\u20134198 (2020).","journal-title":"Cancer Res."},{"issue":"6","key":"33915_CR11","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2021.08.023","volume":"161","author":"P Nallasamy","year":"2021","unstructured":"Nallasamy, P. et al. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 axis. Gastroenterology 161(6), 1998-2013.e7 (2021).","journal-title":"Gastroenterology"},{"issue":"670","key":"33915_CR12","doi-asserted-by":"publisher","first-page":"eadf2947","DOI":"10.1126\/scitranslmed.adf2947","volume":"14","author":"P Sharma","year":"2022","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint therapy: Forging ahead. Sci. Transl. Med. 14(670), eadf2947 (2022).","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"33915_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.22920","volume":"75","author":"AK Miyahira","year":"2015","unstructured":"Miyahira, A. K. et al. Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. Prostate 75(4), 337\u2013347 (2015).","journal-title":"Prostate"},{"issue":"4","key":"33915_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"33915_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27(4), 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"issue":"3","key":"33915_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3), 561\u2013569 (1991).","journal-title":"J. Exp. Med."},{"issue":"6","key":"33915_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1084\/jem.2046fta","volume":"204","author":"H Bashyam","year":"2007","unstructured":"Bashyam, H. CTLA-4: From conflict to clinic. J. Exp. Med. 204(6), 1243\u20131243 (2007).","journal-title":"J. Exp. Med."},{"key":"33915_CR18","doi-asserted-by":"publisher","first-page":"29719","DOI":"10.1038\/srep29719","volume":"6","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci. Rep. 6, 29719 (2016).","journal-title":"Sci. Rep."},{"issue":"8","key":"33915_CR19","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1172\/JCI27856","volume":"116","author":"BT Fife","year":"2006","unstructured":"Fife, B. T. et al. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Investig. 116(8), 2252\u20132261 (2006).","journal-title":"J. Clin. Investig."},{"issue":"2","key":"33915_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tcb.2008.12.001","volume":"19","author":"T Matozaki","year":"2009","unstructured":"Matozaki, T. et al. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19(2), 72\u201380 (2009).","journal-title":"Trends Cell Biol."},{"issue":"1","key":"33915_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung, H. L. et al. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 276(1), 145\u2013164 (2017).","journal-title":"Immunol. Rev."},{"key":"33915_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia (New York, N.Y.) 25, 18\u201327 (2022).","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"8","key":"33915_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. S. et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19(8), 649\u2013658 (2017).","journal-title":"Neoplasia"},{"issue":"21","key":"33915_CR24","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. (Chicago, Ill) 77(21), e108\u2013e110 (2017).","journal-title":"Cancer Res. (Chicago, Ill)"},{"issue":"1","key":"33915_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 17(1), 174\u2013174 (2016).","journal-title":"Genome Biol."},{"issue":"suppl 2","key":"33915_CR26","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley, D. et al. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38(suppl 2), W214\u2013W220 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"33915_CR27","doi-asserted-by":"publisher","first-page":"D877","DOI":"10.1093\/nar\/gkw1012","volume":"45","author":"N Rappaport","year":"2017","unstructured":"Rappaport, N. et al. MalaCards: An amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 45(D1), D877\u2013D887 (2017).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"33915_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"33915_CR29","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"D1","key":"33915_CR30","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M. et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"33915_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/or.2020.7890","volume":"45","author":"Z Guo","year":"2021","unstructured":"Guo, Z. et al. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncol. Rep. 45(2), 523\u2013534 (2021).","journal-title":"Oncol. Rep."},{"issue":"6","key":"33915_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1172154","volume":"5","author":"G Zhang","year":"2016","unstructured":"Zhang, G. et al. A novel role of breast cancer-derived hyaluronan on inducement of M2-like tumor-associated macrophages formation. Oncoimmunology 5(6), e1172154 (2016).","journal-title":"Oncoimmunology"},{"issue":"2","key":"33915_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/biom.12812","volume":"74","author":"Q Liu","year":"2018","unstructured":"Liu, Q. et al. Covariate-adjusted Spearman\u2019s rank correlation with probability-scale residuals. Biometrics 74(2), 595\u2013605 (2018).","journal-title":"Biometrics"},{"issue":"1","key":"33915_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan, B. & Meeks, J. J. T1 bladder cancer: Current considerations for diagnosis and management. Nat. Rev. Urol. 16(1), 23\u201334 (2019).","journal-title":"Nat. Rev. Urol."},{"issue":"2","key":"33915_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","volume":"148","author":"S GuhaSarkar","year":"2010","unstructured":"GuhaSarkar, S. & Banerjee, R. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J. Control. Release 148(2), 147\u2013159 (2010).","journal-title":"J. Control. Release"},{"issue":"19","key":"33915_CR36","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T. et al. Bladder cancer: A review. JAMA, J. Am. Med. Assoc. 324(19), 1980\u20131991 (2020).","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"4","key":"33915_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pathol.2021.10.005","volume":"54","author":"MR Downes","year":"2022","unstructured":"Downes, M. R. et al. The impact of grading scheme on non-muscle invasive bladder cancer progression: Potential utility of hybrid grading schemes. Pathology 54(4), 425\u2013433 (2022).","journal-title":"Pathology"},{"issue":"2","key":"33915_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran, L. et al. Advances in bladder cancer biology and therapy. Nat. Rev. Cancer 21(2), 104\u2013121 (2021).","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"33915_CR39","first-page":"1850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati, M. et al. CD44: A multifunctional mediator of cancer progression. Biomolecules (Basel, Switzerland) 11(12), 1850 (2021).","journal-title":"Biomolecules (Basel, Switzerland)"},{"issue":"4","key":"33915_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41592-021-01112-8","volume":"18","author":"V Marx","year":"2021","unstructured":"Marx, V. Cancer researchers get a grip on immune cell plasticity. Nat. Methods 18(4), 337\u2013341 (2021).","journal-title":"Nat. Methods"},{"key":"33915_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei, X. et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 470, 126\u2013133 (2020).","journal-title":"Cancer Lett."},{"issue":"1","key":"33915_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.yexcr.2019.03.005","volume":"378","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. TNF-\u03b1 derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt\/\u03b2-catenin pathway in SMMC-7721 hepatocellular carcinoma cells. Exp. Cell Res. 378(1), 41\u201350 (2019).","journal-title":"Exp. Cell Res."},{"issue":"12","key":"33915_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P. et al. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med. 50(12), 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"33915_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. Nat. Rev. Immunol. 20(2), 75\u201376 (2020).","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"33915_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","volume":"80","author":"T Kong","year":"2020","unstructured":"Kong, T. et al. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res. 80(3), 444\u2013457 (2020).","journal-title":"Cancer Res."},{"issue":"5","key":"33915_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541\u2013547 (1995).","journal-title":"Immunity"},{"issue":"2","key":"33915_CR47","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/cdd.2010.104","volume":"18","author":"S Lepine","year":"2011","unstructured":"Lepine, S. et al. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ. 18(2), 350\u2013361 (2011).","journal-title":"Cell Death Differ."},{"issue":"26","key":"33915_CR48","doi-asserted-by":"publisher","first-page":"16899","DOI":"10.1073\/pnas.242603899","volume":"99","author":"RL Strausberg","year":"2002","unstructured":"Strausberg, R. L. et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. U. S. A. 99(26), 16899\u201316903 (2002).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"33915_CR49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3579","volume":"13","author":"SK Parks","year":"2013","unstructured":"Parks, S. K., Chiche, J. & Pouyssegur, J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13(9), 611\u2013623 (2013).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"33915_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-018-0923-z","volume":"37","author":"X Guan","year":"2018","unstructured":"Guan, X. et al. Elevated Na\/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. J. Exp. Clin. Cancer Res. 37(1), 255 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"33915_CR51","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/15384101.2018.1464850","volume":"17","author":"M Flinck","year":"2018","unstructured":"Flinck, M. et al. The acid-base transport proteins NHE1 and NBCn1 regulate cell cycle progression in human breast cancer cells. Cell Cycle 17(9), 1056\u20131067 (2018).","journal-title":"Cell Cycle"},{"issue":"5","key":"33915_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/omi.2021.0025","volume":"25","author":"K Dzobo","year":"2021","unstructured":"Dzobo, K. & Sinkala, M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: Immune suppression\/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis. OMICS J. Integr. Biol. 25(5), 313\u2013332 (2021).","journal-title":"OMICS J. Integr. Biol."},{"key":"33915_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fgene.2014.00152","volume":"5","author":"N Servant","year":"2014","unstructured":"Servant, N. et al. Bioinformatics for precision medicine in oncology: Principles and application to the SHIVA clinical trial. Front. Genet. 5, 152\u2013152 (2014).","journal-title":"Front. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33915-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:02:50Z","timestamp":1686744170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33915"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33915-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2528355\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9657"}}